 Max Wohlauer
Concepts (388)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Surgical Procedures | 18 | 2024 | 303 | 3.860 |
Why?
| | Endovascular Procedures | 9 | 2024 | 312 | 1.820 |
Why?
| | Thrombosis | 3 | 2025 | 371 | 1.520 |
Why?
| | Peripheral Arterial Disease | 5 | 2025 | 475 | 1.280 |
Why?
| | Ischemia | 7 | 2025 | 409 | 1.230 |
Why?
| | Surgeons | 7 | 2024 | 297 | 1.200 |
Why?
| | Blood Coagulation Disorders | 10 | 2016 | 173 | 1.200 |
Why?
| | Arterial Occlusive Diseases | 2 | 2025 | 83 | 1.100 |
Why?
| | Blood Vessel Prosthesis Implantation | 6 | 2022 | 202 | 1.080 |
Why?
| | Shock, Hemorrhagic | 10 | 2024 | 167 | 1.060 |
Why?
| | Thrombelastography | 13 | 2020 | 154 | 1.040 |
Why?
| | Acute Lung Injury | 8 | 2015 | 287 | 1.000 |
Why?
| | Vascular System Injuries | 3 | 2023 | 71 | 0.990 |
Why?
| | Elective Surgical Procedures | 3 | 2024 | 179 | 0.950 |
Why?
| | Aortic Aneurysm, Abdominal | 4 | 2022 | 140 | 0.920 |
Why?
| | Wounds and Injuries | 13 | 2016 | 758 | 0.890 |
Why?
| | Extremities | 1 | 2025 | 131 | 0.890 |
Why?
| | Baseball | 1 | 2025 | 63 | 0.890 |
Why?
| | Brachial Artery | 1 | 2025 | 205 | 0.850 |
Why?
| | Leg Injuries | 1 | 2023 | 25 | 0.810 |
Why?
| | Diabetic Foot | 1 | 2022 | 24 | 0.790 |
Why?
| | Intermittent Claudication | 2 | 2022 | 118 | 0.790 |
Why?
| | Burnout, Professional | 4 | 2021 | 442 | 0.750 |
Why?
| | Blood Transfusion | 8 | 2016 | 325 | 0.720 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 373 | 0.690 |
Why?
| | Coronavirus Infections | 3 | 2020 | 364 | 0.690 |
Why?
| | Sexism | 1 | 2021 | 61 | 0.690 |
Why?
| | Mental Health | 3 | 2022 | 726 | 0.680 |
Why?
| | Ergonomics | 1 | 2020 | 26 | 0.680 |
Why?
| | Cultural Diversity | 1 | 2021 | 77 | 0.670 |
Why?
| | Proteomics | 4 | 2025 | 1111 | 0.670 |
Why?
| | Musculoskeletal Pain | 1 | 2020 | 37 | 0.670 |
Why?
| | Aortic Aneurysm, Thoracic | 3 | 2017 | 131 | 0.660 |
Why?
| | Internship and Residency | 4 | 2020 | 1147 | 0.630 |
Why?
| | Multiple Organ Failure | 4 | 2013 | 128 | 0.630 |
Why?
| | Muscle Fatigue | 1 | 2020 | 102 | 0.630 |
Why?
| | Aggression | 1 | 2021 | 202 | 0.630 |
Why?
| | Foot | 1 | 2020 | 96 | 0.620 |
Why?
| | Tendons | 1 | 2020 | 111 | 0.610 |
Why?
| | Continuity of Patient Care | 2 | 2012 | 284 | 0.610 |
Why?
| | Racism | 1 | 2021 | 135 | 0.610 |
Why?
| | Pandemics | 8 | 2023 | 1639 | 0.610 |
Why?
| | Betacoronavirus | 3 | 2020 | 270 | 0.600 |
Why?
| | Axillary Artery | 2 | 2015 | 12 | 0.590 |
Why?
| | Occupational Diseases | 1 | 2020 | 156 | 0.590 |
Why?
| | Lymph | 3 | 2015 | 32 | 0.580 |
Why?
| | Running | 1 | 2020 | 230 | 0.550 |
Why?
| | Serum Albumin, Human | 1 | 2017 | 6 | 0.540 |
Why?
| | Vascular Diseases | 1 | 2020 | 243 | 0.540 |
Why?
| | Hypoalbuminemia | 1 | 2017 | 30 | 0.540 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1171 | 0.530 |
Why?
| | Curriculum | 3 | 2019 | 992 | 0.500 |
Why?
| | Research Design | 1 | 2022 | 1139 | 0.490 |
Why?
| | Blood Platelet Disorders | 2 | 2013 | 9 | 0.490 |
Why?
| | Axilla | 1 | 2015 | 47 | 0.480 |
Why?
| | Humans | 67 | 2025 | 137585 | 0.470 |
Why?
| | Treatment Outcome | 20 | 2025 | 10811 | 0.470 |
Why?
| | Aneurysm, False | 1 | 2015 | 48 | 0.470 |
Why?
| | Fibrinolysis | 4 | 2025 | 146 | 0.460 |
Why?
| | Osteosarcoma | 1 | 2015 | 74 | 0.460 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 115 | 0.440 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1040 | 0.430 |
Why?
| | Male | 44 | 2025 | 67762 | 0.420 |
Why?
| | Bone Neoplasms | 1 | 2015 | 247 | 0.400 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 24 | 0.400 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2021 | 1329 | 0.390 |
Why?
| | Physicians | 1 | 2021 | 910 | 0.390 |
Why?
| | Patient Handoff | 1 | 2012 | 32 | 0.390 |
Why?
| | Neutrophils | 4 | 2015 | 1238 | 0.390 |
Why?
| | Saline Solution, Hypertonic | 1 | 2012 | 41 | 0.390 |
Why?
| | Duodenal Neoplasms | 1 | 2012 | 23 | 0.380 |
Why?
| | Acute Disease | 6 | 2025 | 1007 | 0.380 |
Why?
| | Carcinoma, Papillary | 1 | 2013 | 81 | 0.380 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2012 | 30 | 0.380 |
Why?
| | Decompression, Surgical | 2 | 2025 | 106 | 0.380 |
Why?
| | Ampulla of Vater | 1 | 2012 | 42 | 0.380 |
Why?
| | Colonic Diseases | 1 | 2012 | 33 | 0.380 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2012 | 96 | 0.380 |
Why?
| | Pancreatic Ducts | 1 | 2013 | 85 | 0.380 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2012 | 57 | 0.380 |
Why?
| | Intestinal Volvulus | 1 | 2012 | 22 | 0.380 |
Why?
| | Blood Coagulation | 5 | 2021 | 255 | 0.370 |
Why?
| | Hemodilution | 1 | 2011 | 10 | 0.360 |
Why?
| | Multiple Trauma | 1 | 2012 | 100 | 0.360 |
Why?
| | Wounds, Penetrating | 1 | 2012 | 65 | 0.360 |
Why?
| | Female | 40 | 2025 | 73304 | 0.350 |
Why?
| | Patient Care Management | 1 | 2011 | 57 | 0.350 |
Why?
| | General Surgery | 1 | 2012 | 173 | 0.340 |
Why?
| | Time-to-Treatment | 2 | 2024 | 205 | 0.330 |
Why?
| | Rats, Sprague-Dawley | 9 | 2015 | 2486 | 0.330 |
Why?
| | Wounds, Nonpenetrating | 2 | 2015 | 278 | 0.330 |
Why?
| | Mesentery | 4 | 2015 | 48 | 0.320 |
Why?
| | Patient Transfer | 1 | 2012 | 176 | 0.320 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2024 | 261 | 0.310 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2013 | 289 | 0.310 |
Why?
| | Resuscitation | 3 | 2024 | 251 | 0.310 |
Why?
| | Risk Assessment | 9 | 2021 | 3457 | 0.290 |
Why?
| | Platelet Aggregation Inhibitors | 5 | 2022 | 463 | 0.280 |
Why?
| | Adult | 27 | 2025 | 37929 | 0.280 |
Why?
| | Time Factors | 9 | 2025 | 6828 | 0.270 |
Why?
| | Thrombophilia | 2 | 2021 | 83 | 0.270 |
Why?
| | Risk Factors | 10 | 2025 | 10388 | 0.260 |
Why?
| | Computer Simulation | 1 | 2011 | 978 | 0.260 |
Why?
| | Anticoagulants | 4 | 2021 | 664 | 0.250 |
Why?
| | Rats | 8 | 2014 | 5647 | 0.250 |
Why?
| | Middle Aged | 23 | 2025 | 33479 | 0.250 |
Why?
| | Blood Platelets | 4 | 2014 | 408 | 0.250 |
Why?
| | Software | 1 | 2011 | 665 | 0.250 |
Why?
| | Retrospective Studies | 10 | 2025 | 15657 | 0.240 |
Why?
| | Median Arcuate Ligament Syndrome | 1 | 2025 | 8 | 0.240 |
Why?
| | Celiac Artery | 1 | 2025 | 17 | 0.240 |
Why?
| | Aged | 12 | 2025 | 23961 | 0.240 |
Why?
| | Adaptation, Psychological | 2 | 2021 | 655 | 0.240 |
Why?
| | Education, Medical, Graduate | 2 | 2021 | 486 | 0.240 |
Why?
| | Balloon Occlusion | 2 | 2024 | 34 | 0.240 |
Why?
| | Adenocarcinoma | 1 | 2012 | 940 | 0.240 |
Why?
| | Prospective Studies | 9 | 2022 | 7604 | 0.230 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1483 | 0.230 |
Why?
| | Hospitals, Public | 1 | 2025 | 29 | 0.230 |
Why?
| | Thrombectomy | 1 | 2025 | 69 | 0.230 |
Why?
| | Angiography | 2 | 2023 | 207 | 0.230 |
Why?
| | Pancreatic Neoplasms | 1 | 2013 | 938 | 0.230 |
Why?
| | Lower Extremity | 3 | 2023 | 427 | 0.220 |
Why?
| | Health Surveys | 3 | 2021 | 514 | 0.220 |
Why?
| | Varicose Veins | 1 | 2024 | 17 | 0.220 |
Why?
| | Kidney | 1 | 2012 | 1468 | 0.210 |
Why?
| | Patient Care Team | 2 | 2024 | 631 | 0.210 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 316 | 0.210 |
Why?
| | Injury Severity Score | 7 | 2016 | 522 | 0.210 |
Why?
| | Occupational Health | 3 | 2021 | 200 | 0.210 |
Why?
| | Brain Injuries | 3 | 2014 | 494 | 0.210 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2014 | 34 | 0.210 |
Why?
| | Robotic Surgical Procedures | 1 | 2025 | 130 | 0.210 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 49 | 0.200 |
Why?
| | Physician-Patient Relations | 2 | 2021 | 548 | 0.200 |
Why?
| | Arachidonic Acid | 2 | 2014 | 120 | 0.200 |
Why?
| | Hospital Mortality | 2 | 2021 | 911 | 0.200 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 65 | 0.200 |
Why?
| | Specialties, Surgical | 2 | 2020 | 75 | 0.190 |
Why?
| | Carotid Stenosis | 1 | 2023 | 91 | 0.190 |
Why?
| | Blood Coagulation Tests | 2 | 2020 | 67 | 0.190 |
Why?
| | Prevalence | 3 | 2020 | 2734 | 0.190 |
Why?
| | Iliac Aneurysm | 1 | 2022 | 19 | 0.190 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 117 | 0.190 |
Why?
| | United States | 10 | 2024 | 14841 | 0.190 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 226 | 0.190 |
Why?
| | Peripheral Vascular Diseases | 1 | 2022 | 103 | 0.180 |
Why?
| | Point-of-Care Systems | 3 | 2012 | 167 | 0.180 |
Why?
| | Aorta | 1 | 2024 | 417 | 0.180 |
Why?
| | Arteriovenous Fistula | 1 | 2021 | 36 | 0.180 |
Why?
| | Aortic Rupture | 1 | 2021 | 25 | 0.180 |
Why?
| | Iliac Vein | 1 | 2021 | 13 | 0.180 |
Why?
| | Work Capacity Evaluation | 1 | 2020 | 11 | 0.170 |
Why?
| | Culturally Competent Care | 1 | 2021 | 63 | 0.170 |
Why?
| | Catheters | 1 | 2021 | 73 | 0.170 |
Why?
| | Vena Cava, Inferior | 1 | 2021 | 71 | 0.170 |
Why?
| | Tenotomy | 1 | 2020 | 15 | 0.170 |
Why?
| | Physicians, Women | 1 | 2021 | 83 | 0.160 |
Why?
| | Tendon Transfer | 1 | 2020 | 23 | 0.160 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 67 | 0.160 |
Why?
| | Catheterization, Peripheral | 1 | 2021 | 109 | 0.160 |
Why?
| | International Cooperation | 1 | 2020 | 198 | 0.160 |
Why?
| | Posture | 1 | 2020 | 185 | 0.160 |
Why?
| | Workload | 3 | 2021 | 167 | 0.150 |
Why?
| | Thromboembolism | 1 | 2020 | 119 | 0.150 |
Why?
| | Partnership Practice | 1 | 2018 | 4 | 0.150 |
Why?
| | Societies, Medical | 2 | 2020 | 820 | 0.150 |
Why?
| | Insurance Benefits | 1 | 2018 | 11 | 0.150 |
Why?
| | Mentors | 1 | 2021 | 202 | 0.150 |
Why?
| | Infection Control | 1 | 2020 | 167 | 0.150 |
Why?
| | Venous Thrombosis | 1 | 2021 | 190 | 0.150 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 112 | 0.150 |
Why?
| | Physical Endurance | 1 | 2020 | 275 | 0.150 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 273 | 0.150 |
Why?
| | Pain Measurement | 1 | 2020 | 521 | 0.140 |
Why?
| | Medically Uninsured | 1 | 2018 | 130 | 0.140 |
Why?
| | Surveys and Questionnaires | 7 | 2022 | 5778 | 0.140 |
Why?
| | Triage | 1 | 2020 | 222 | 0.140 |
Why?
| | Walking | 1 | 2022 | 529 | 0.140 |
Why?
| | Insurance Coverage | 1 | 2018 | 230 | 0.130 |
Why?
| | Statistics, Nonparametric | 3 | 2014 | 431 | 0.130 |
Why?
| | Registries | 2 | 2024 | 2035 | 0.130 |
Why?
| | Biomechanical Phenomena | 1 | 2020 | 810 | 0.130 |
Why?
| | Nutrition Assessment | 1 | 2017 | 92 | 0.130 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2014 | 66 | 0.130 |
Why?
| | Insurance, Health | 1 | 2018 | 283 | 0.130 |
Why?
| | Chronic Disease | 3 | 2024 | 1793 | 0.120 |
Why?
| | Recovery of Function | 1 | 2020 | 653 | 0.120 |
Why?
| | Hemostatic Techniques | 1 | 2016 | 46 | 0.120 |
Why?
| | Postoperative Complications | 3 | 2025 | 2654 | 0.120 |
Why?
| | Receptor, PAR-2 | 1 | 2015 | 6 | 0.120 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2015 | 26 | 0.120 |
Why?
| | Exsanguination | 2 | 2012 | 19 | 0.120 |
Why?
| | Aged, 80 and over | 5 | 2025 | 7635 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 1313 | 0.120 |
Why?
| | Motor Activity | 1 | 2020 | 718 | 0.120 |
Why?
| | Plasminogen | 1 | 2015 | 30 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1587 | 0.120 |
Why?
| | Sex Factors | 1 | 2021 | 2071 | 0.120 |
Why?
| | Myocardial Infarction | 1 | 2022 | 1046 | 0.120 |
Why?
| | Geriatric Assessment | 1 | 2017 | 224 | 0.120 |
Why?
| | Cohort Studies | 3 | 2022 | 5742 | 0.120 |
Why?
| | Microcirculation | 1 | 2015 | 149 | 0.110 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2015 | 93 | 0.110 |
Why?
| | Biomedical Research | 1 | 2021 | 692 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 889 | 0.110 |
Why?
| | Stroke | 1 | 2023 | 1120 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 657 | 0.110 |
Why?
| | Medicaid | 1 | 2018 | 435 | 0.110 |
Why?
| | Blood Vessel Prosthesis | 3 | 2022 | 127 | 0.110 |
Why?
| | Thrombin | 2 | 2015 | 152 | 0.110 |
Why?
| | Odds Ratio | 1 | 2017 | 1070 | 0.110 |
Why?
| | Animals | 10 | 2015 | 36940 | 0.110 |
Why?
| | Frailty | 1 | 2017 | 170 | 0.110 |
Why?
| | Chi-Square Distribution | 2 | 2012 | 530 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1266 | 0.110 |
Why?
| | Limb Salvage | 2 | 2025 | 57 | 0.100 |
Why?
| | Subclavian Artery | 1 | 2013 | 28 | 0.100 |
Why?
| | Prosthesis Design | 3 | 2022 | 327 | 0.100 |
Why?
| | Medicare | 1 | 2018 | 773 | 0.100 |
Why?
| | Carotid Artery, Common | 1 | 2013 | 36 | 0.100 |
Why?
| | Fibrinogen | 1 | 2014 | 168 | 0.100 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2012 | 652 | 0.100 |
Why?
| | History, 17th Century | 1 | 2012 | 16 | 0.100 |
Why?
| | History, 18th Century | 1 | 2012 | 19 | 0.100 |
Why?
| | Brazil | 2 | 2025 | 167 | 0.100 |
Why?
| | Comorbidity | 2 | 2021 | 1622 | 0.100 |
Why?
| | History, 19th Century | 1 | 2012 | 60 | 0.100 |
Why?
| | Sigmoid Diseases | 1 | 2012 | 12 | 0.100 |
Why?
| | Social Responsibility | 1 | 2012 | 51 | 0.100 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2012 | 43 | 0.100 |
Why?
| | Isoflurane | 1 | 2012 | 31 | 0.100 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1724 | 0.100 |
Why?
| | Anesthetics, Inhalation | 1 | 2012 | 35 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 107 | 0.100 |
Why?
| | Colorado | 5 | 2016 | 4565 | 0.100 |
Why?
| | Nebulizers and Vaporizers | 1 | 2012 | 86 | 0.090 |
Why?
| | Biopsy, Needle | 1 | 2012 | 189 | 0.090 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2011 | 6 | 0.090 |
Why?
| | Narration | 1 | 2012 | 58 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1100 | 0.090 |
Why?
| | Blood Transfusion, Autologous | 1 | 2011 | 17 | 0.090 |
Why?
| | Trauma Severity Indices | 1 | 2012 | 106 | 0.090 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2011 | 43 | 0.090 |
Why?
| | Social Values | 1 | 2012 | 36 | 0.090 |
Why?
| | Multivariate Analysis | 2 | 2013 | 1509 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2012 | 140 | 0.090 |
Why?
| | Random Allocation | 1 | 2012 | 353 | 0.090 |
Why?
| | Colectomy | 1 | 2012 | 100 | 0.090 |
Why?
| | Kidney Function Tests | 1 | 2012 | 160 | 0.090 |
Why?
| | Extravascular Lung Water | 1 | 2011 | 7 | 0.090 |
Why?
| | Renal Replacement Therapy | 1 | 2012 | 92 | 0.090 |
Why?
| | Depression | 1 | 2020 | 1397 | 0.090 |
Why?
| | Survival Rate | 2 | 2016 | 1972 | 0.090 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2011 | 35 | 0.090 |
Why?
| | History, 20th Century | 1 | 2012 | 325 | 0.090 |
Why?
| | Docosahexaenoic Acids | 1 | 2011 | 84 | 0.090 |
Why?
| | Hypothermia | 1 | 2011 | 36 | 0.090 |
Why?
| | Abdominal Pain | 1 | 2012 | 145 | 0.090 |
Why?
| | Abdominal Injuries | 1 | 2012 | 123 | 0.090 |
Why?
| | Oxidative Stress | 3 | 2014 | 1317 | 0.090 |
Why?
| | Aorta, Thoracic | 1 | 2013 | 267 | 0.090 |
Why?
| | Administration, Inhalation | 1 | 2012 | 688 | 0.090 |
Why?
| | Efficiency | 1 | 2011 | 99 | 0.080 |
Why?
| | Quality Assurance, Health Care | 1 | 2012 | 322 | 0.080 |
Why?
| | Adolescent | 6 | 2025 | 21513 | 0.080 |
Why?
| | Health Care Surveys | 2 | 2024 | 565 | 0.080 |
Why?
| | Superoxides | 1 | 2011 | 202 | 0.080 |
Why?
| | Pancreatectomy | 1 | 2013 | 253 | 0.080 |
Why?
| | Trauma Centers | 4 | 2016 | 421 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2012 | 283 | 0.080 |
Why?
| | Acidosis | 1 | 2011 | 101 | 0.080 |
Why?
| | Proteome | 1 | 2014 | 472 | 0.080 |
Why?
| | Biomarkers | 3 | 2017 | 4149 | 0.080 |
Why?
| | Endothelial Cells | 1 | 2015 | 785 | 0.080 |
Why?
| | Logistic Models | 2 | 2012 | 2074 | 0.080 |
Why?
| | Models, Animal | 1 | 2011 | 384 | 0.080 |
Why?
| | Safety | 1 | 2011 | 338 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 5472 | 0.080 |
Why?
| | Quality Improvement | 2 | 2021 | 1178 | 0.080 |
Why?
| | Recurrence | 1 | 2012 | 1060 | 0.080 |
Why?
| | Reperfusion Injury | 1 | 2011 | 279 | 0.070 |
Why?
| | Lymph Nodes | 1 | 2011 | 491 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1738 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 2014 | 4295 | 0.070 |
Why?
| | Tissue and Organ Procurement | 1 | 2012 | 321 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1946 | 0.070 |
Why?
| | Lung | 3 | 2015 | 4060 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 740 | 0.070 |
Why?
| | Prognosis | 2 | 2013 | 4030 | 0.060 |
Why?
| | Chromatography, Liquid | 3 | 2014 | 433 | 0.060 |
Why?
| | Communication | 1 | 2012 | 879 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 532 | 0.060 |
Why?
| | Embolectomy | 1 | 2025 | 13 | 0.060 |
Why?
| | Operative Time | 1 | 2025 | 145 | 0.060 |
Why?
| | Young Adult | 6 | 2025 | 13209 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2804 | 0.060 |
Why?
| | Clinical Competence | 1 | 2012 | 1118 | 0.050 |
Why?
| | Databases, Factual | 2 | 2021 | 1357 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2012 | 1069 | 0.050 |
Why?
| | Platelet Function Tests | 2 | 2014 | 27 | 0.050 |
Why?
| | Aortography | 2 | 2013 | 52 | 0.050 |
Why?
| | Interdisciplinary Communication | 1 | 2024 | 191 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3284 | 0.050 |
Why?
| | Receptors, Purinergic P2 | 2 | 2013 | 23 | 0.050 |
Why?
| | Platelet Activation | 2 | 2014 | 93 | 0.050 |
Why?
| | Mesenteric Artery, Inferior | 1 | 2022 | 2 | 0.050 |
Why?
| | Off-Label Use | 1 | 2022 | 52 | 0.050 |
Why?
| | Iliac Artery | 1 | 2022 | 55 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 206 | 0.050 |
Why?
| | Product Labeling | 1 | 2021 | 10 | 0.040 |
Why?
| | Cooperative Behavior | 1 | 2024 | 451 | 0.040 |
Why?
| | Blood Component Transfusion | 2 | 2012 | 84 | 0.040 |
Why?
| | Phlebography | 1 | 2021 | 38 | 0.040 |
Why?
| | Mitochondrial Proteins | 2 | 2015 | 257 | 0.040 |
Why?
| | Depersonalization | 1 | 2020 | 7 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2691 | 0.040 |
Why?
| | Protective Factors | 1 | 2021 | 93 | 0.040 |
Why?
| | Work-Life Balance | 1 | 2020 | 22 | 0.040 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2020 | 9 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2022 | 255 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
| | Partial Thromboplastin Time | 1 | 2020 | 57 | 0.040 |
Why?
| | Heparin | 1 | 2021 | 261 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2020 | 82 | 0.040 |
Why?
| | Aspirin | 1 | 2022 | 387 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 2057 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 547 | 0.040 |
Why?
| | Popliteal Artery | 1 | 2018 | 59 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 322 | 0.040 |
Why?
| | Hemorrhage | 1 | 2022 | 722 | 0.040 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2018 | 103 | 0.040 |
Why?
| | Stents | 1 | 2022 | 527 | 0.030 |
Why?
| | Military Personnel | 1 | 2024 | 544 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 386 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 364 | 0.030 |
Why?
| | Career Choice | 1 | 2019 | 219 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1710 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2021 | 556 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2020 | 435 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1050 | 0.030 |
Why?
| | Alarmins | 1 | 2015 | 26 | 0.030 |
Why?
| | Emotions | 1 | 2020 | 548 | 0.030 |
Why?
| | Bacterial Translocation | 1 | 2015 | 43 | 0.030 |
Why?
| | Pain | 1 | 2020 | 756 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2014 | 3556 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 139 | 0.030 |
Why?
| | Tranexamic Acid | 1 | 2015 | 40 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 827 | 0.030 |
Why?
| | Mesenteric Artery, Superior | 1 | 2013 | 17 | 0.030 |
Why?
| | Inflammation | 2 | 2015 | 2837 | 0.030 |
Why?
| | Renal Artery | 1 | 2013 | 37 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 2014 | 153 | 0.030 |
Why?
| | Glasgow Coma Scale | 1 | 2014 | 186 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 499 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 3295 | 0.030 |
Why?
| | Platelet Count | 1 | 2013 | 86 | 0.030 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2012 | 6 | 0.020 |
Why?
| | Blood Proteins | 1 | 2014 | 252 | 0.020 |
Why?
| | Leukotriene C4 | 1 | 2012 | 11 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2013 | 153 | 0.020 |
Why?
| | Leukotriene B4 | 1 | 2012 | 42 | 0.020 |
Why?
| | Reference Values | 1 | 2014 | 816 | 0.020 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2012 | 37 | 0.020 |
Why?
| | Ticlopidine | 1 | 2012 | 52 | 0.020 |
Why?
| | Eicosanoids | 1 | 2012 | 62 | 0.020 |
Why?
| | Peroxidase | 1 | 2012 | 175 | 0.020 |
Why?
| | Cell Membrane | 1 | 2015 | 738 | 0.020 |
Why?
| | Dinoprostone | 1 | 2012 | 191 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2012 | 390 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1178 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2014 | 739 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2011 | 67 | 0.020 |
Why?
| | Cerebrovascular Circulation | 1 | 2013 | 243 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2018 | 986 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1060 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 345 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2892 | 0.020 |
Why?
| | Waiting Lists | 1 | 2012 | 266 | 0.020 |
Why?
| | Hemolysis | 1 | 2011 | 206 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 412 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2011 | 500 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2012 | 2167 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2011 | 771 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5131 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4193 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 5757 | 0.010 |
Why?
| | Mice | 1 | 2012 | 17787 | 0.010 |
Why?
|
|
Wohlauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|